@article{cba16804b1cb4735ac2dc8d33ed1e0f7,
title = "Trends and Outcomes of Fibrinolytic Therapy for STEMI: Insights and Reflections in the COVID-19 Era",
author = "Ayman Elbadawi and Dhruv Mahtta and Elgendy, \{Islam Y.\} and Marwan Saad and Chayakrit Krittanawong and Hira, \{Ravi S.\} and Mohamed Omer and Ogunbayo, \{Gbolahan O.\} and Kirk Garratt and Rao, \{Sunil V.\} and Hani Jneid",
note = "Funding Information: Dr. Garratt has received honoraria for serving on clinical events adjudication committees from Abbott Vascular and Jarvik Heart; and is a cofounder of and holds an equity position in LifeCuff Technologies, Inc. Dr. Rao has received research funding to his institution from Bayer, Shockwave Medical, and Svelte Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. †Drs. Elbadawi and Mahtta contributed equally to this work.",
year = "2020",
month = oct,
day = "12",
doi = "10.1016/j.jcin.2020.07.004",
language = "English (US)",
volume = "13",
pages = "2312--2314",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "19",
}